X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
DCP-001 (vididencel) is an off-the-shelf intradermal allogenic dendritic cell-based vaccine, which is being evaluated for the treatment of acute myeloid leukemia.
Lead Product(s): Vididencel
Therapeutic Area: Oncology Product Name: DCP-001
Highest Development Status: Phase IIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 12, 2024
Details:
The collaboration aims to support Mendus to focus on the development of its lead product candidate DCP-001 (vididencel) in combination with oral azacitidine as a potential novel maintenance treatment in acute myeloid leukemia.
Lead Product(s): Vididencel,Azacitidine
Therapeutic Area: Oncology Product Name: DCP-001
Highest Development Status: IND EnablingProduct Type: Vaccine
Partner/Sponsor/Collaborator: Australasian Leukaemia & Lymphoma Group
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration December 06, 2023
Details:
DCP-001 (vididencel), an allogeneic dendritic cell vaccine, which is investigated for the treatment of acute myeloid leukemia and ovarian cancer and received for fast track designation from the U.S. Food and Drug Administration.
Lead Product(s): Vididencel
Therapeutic Area: Oncology Product Name: DCP-001
Highest Development Status: Phase IIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 08, 2023
Details:
Mendus intends will use the net proceeds for the clinical development of DCP-001 (vididencel), an allogeneic dendritic cell vaccine, in AML maintenance and ovarian cancer.
Lead Product(s): Vididencel
Therapeutic Area: Oncology Product Name: DCP-001
Highest Development Status: Phase IIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Flerie
Deal Size: $29.2 million Upfront Cash: Undisclosed
Deal Type: Financing June 08, 2023
Details:
DCP-001 is currently being evaluated in the ADVANCE II Phase 2 clinical trial to prevent cases of tumor recurrence in Acute Myeloid Leukemia (AML) and in the ALISON Phase 1 clinical trial in ovarian cancer.
Lead Product(s): DCP-001
Therapeutic Area: Oncology Product Name: DCP-001
Highest Development Status: Phase IIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Minaris
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement October 17, 2022
Details:
The initial data demonstrates that DCP-001, an off-the-shelf intradermal dendritic cell-based vaccine was safe and well-tolerated, confirming the benign safety profile of DCP-001 observed in multiple completed and ongoing clinical trials.
Lead Product(s): DCP-001
Therapeutic Area: Oncology Product Name: DCP-001
Highest Development Status: Phase IProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 17, 2022
Details:
Intratumoral injection of allogeneic pro-inflammatory dendritic cells (ilixadencel) substantially and sustainably enhanced an otherwise ineffective systemic anti CTLA-4 treatment in an established in vivo cancer model.
Lead Product(s): Ilixadencel
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 14, 2022
Details:
Ilixadencel (activated allogeneic dendritic cells) is an off-the-shelf cell-based cancer immunotherapy developed for the treatment of solid tumors, has consistently demonstrated signs of efficacy and maintained a positive safety and tolerability profile.
Lead Product(s): Activated Allogeneic Dendritic Cells
Therapeutic Area: Oncology Product Name: Ilixadencel
Highest Development Status: Phase IProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 09, 2022
Details:
Analysis of primary study endpoint was completed with 7 patients showing a measurable residual disease (MRD) response, of which 5 patients converted from MRD+ to MRD- and 2 patients showed a substantial, at least 10-fold reduction in MRD following treatment with DCP-001.
Lead Product(s): DCP-001
Therapeutic Area: Oncology Product Name: DCP-001
Highest Development Status: Phase IIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 16, 2022
Details:
In vivo and in vitro data support evaluation of DCP-001 as a potential combination therapy with 5-AZA+VEN in AML and related hematological malignancies and demonstrated stronger tumor volume reduction in combination than either vaccination or drug treatment alone.
Lead Product(s): DCP-001,Azacitidine,Venetoclax
Therapeutic Area: Oncology Product Name: DCP-001
Highest Development Status: PreclinicalProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 03, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
